← FDA Drug Approvals (Drugs@FDA)

IMIPENEM AND CILASTATIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: HQ SPCLT PHARMA · Approved 2019-12-12

Drug application

FDA Application #

ANDA207594

Application type

Abbreviated New Drug Application (Generic)

Brand name

IMIPENEM AND CILASTATIN

Generic name

IMIPENEM AND CILASTATIN

Active ingredients

CILASTATIN SODIUM; IMIPENEM

Dosage form

POWDER

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

HQ SPCLT PHARMA

Manufacturer

WG Critical Care, LLC

First approval

2019-12-12

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown